DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma
- PMID: 9809552
- DOI: 10.1038/3266
DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma
Abstract
Vaccination with idiotypic protein protects against B-cell lymphoma, mainly through anti-idiotypic antibody. For use in patients, DNA vaccines containing single-chain Fv derived from tumor provide a convenient alternative vaccine delivery system. However, single-chain Fv sequence alone induces low anti-idiotypic response and poor protection against lymphoma. Fusion of the gene encoding fragment C of tetanus toxin to single-chain Fv substantially promotes the anti-idiotypic response and induces strong protection against B-cell lymphoma. The same fusion design also induces protective immunity against a surface Ig-negative myeloma. These findings indicate that fusion to a pathogen sequence allows a tumor antigen to engage diverse immune mechanisms that suppress growth. This fusion design has the added advantage of overcoming potential tolerance to tumor that may exist in patients.
Comment in
-
Giving DNA vaccines a helping hand.Nat Med. 1998 Nov;4(11):1239-40. doi: 10.1038/3217. Nat Med. 1998. PMID: 9809542 No abstract available.
Similar articles
-
DNA vaccines against lymphoma: promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C.J Immunol. 1997 Aug 15;159(4):1885-92. J Immunol. 1997. PMID: 9257853
-
Plant viral genes in DNA idiotypic vaccines activate linked CD4+ T-cell mediated immunity against B-cell malignancies.Nat Biotechnol. 2001 Aug;19(8):760-4. doi: 10.1038/90816. Nat Biotechnol. 2001. PMID: 11479570
-
Vaccination with DNA encoding a single-chain TCR fusion protein induces anticlonotypic immunity and protects against T-cell lymphoma.Cancer Res. 2002 Mar 15;62(6):1757-60. Cancer Res. 2002. PMID: 11912151
-
DNA fusion gene vaccines against cancer: from the laboratory to the clinic.Immunol Rev. 2004 Jun;199:156-80. doi: 10.1111/j.0105-2896.2004.00145.x. Immunol Rev. 2004. PMID: 15233733 Review.
-
Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.Haematologica. 2002 Sep;87(9):989-1001. Haematologica. 2002. PMID: 12217812 Review.
Cited by
-
Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-antigen positive tumors.Cancer Immunol Immunother. 2007 Dec;56(12):2003-16. doi: 10.1007/s00262-007-0299-y. Epub 2007 Feb 23. Cancer Immunol Immunother. 2007. PMID: 17333181 Free PMC article.
-
Idiotypes as immunogens: facing the challenge of inducing strong therapeutic immune responses against the variable region of immunoglobulins.Front Oncol. 2012 Nov 9;2:159. doi: 10.3389/fonc.2012.00159. eCollection 2012. Front Oncol. 2012. PMID: 23162790 Free PMC article.
-
Vaccination strategies for lymphomas.Curr Oncol Rep. 2003 Sep;5(5):380-6. doi: 10.1007/s11912-003-0022-x. Curr Oncol Rep. 2003. PMID: 12895388 Review.
-
Recombinant baculovirus expressing the FrC-OVA protein induces protective antitumor immunity in an EG7-OVA mouse model.J Biol Eng. 2019 Oct 22;13:77. doi: 10.1186/s13036-019-0207-y. eCollection 2019. J Biol Eng. 2019. PMID: 31649751 Free PMC article.
-
Enhancement of DNA vaccine potency through linkage of antigen to filamentous bacteriophage coat protein III domain I.Immunology. 2006 Apr;117(4):502-6. doi: 10.1111/j.1365-2567.2006.02325.x. Immunology. 2006. PMID: 16556264 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical